���构特征与受体作用机制 — Beginner to Advanced

By Editorial Desk · published 2025-09-18 · last reviewed 2025-10-20 · Topic

The short version of half-life fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Handling, Storage, and Analysis

Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.

Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.

Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.

Semaglutide at a glance

Background and Mechanism of Action

Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.

Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.

Related pages on this site

• Smart toolkit
• Regional reference
• Smart toolkit
• Comprehensive guide
• Tracked briefing
• Adaptive reference
• Verified notes
• Modern workbook

Storage Stability and Analytical Control

As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.

Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.

Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.

Peptide Background and Receptor Mechanism

The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.

Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.

Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.

Handling, Storage, and Quality Control

Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.

Peptide degradation follows several routes. Hydrolysis cleaves the backbone at susceptible residues, oxidation targets methionine and tryptophan side chains, and aggregation produces higher-molecular-weight species that are difficult to reverse. Light exposure accelerates oxidation, which is why amber glass or opaque secondary packaging is common. Repeated freeze-thaw cycles promote aggregation and are best avoided. Stability-indicating methods detect these changes before they become visible.

Quality control for research material typically involves reversed-phase HPLC for purity and identity, mass spectrometry for molecular weight confirmation, and Karl Fischer titration for residual water content. Peptide content is often reported as the mass of actual peptide rather than total powder mass, since counterions and water contribute to the latter. A certificate of analysis should list the method used for each specification. Limits and acceptance criteria vary by supplier and by intended application.

Reference notes

Tartaric acid, an acid that forms diastereomeric salts with chiral amines Antimony potassium tartrate, an anion, that forms diastereomeric salts with chiral cations. Mandelic acid, an acid that forms diastereomeric salts with chiral amines. Camphorsulfonic acid, an acid that forms diastereomeric salts with chiral amines. Also 3-bromocamphor-8-sulfonic acid 1-Phenylethylamine, a base that forms diastereomeric salts with chiral acids. Many related chiral amines have been demonstrated.

Grave fields are one of the chief sources of information on prehistoric cultures, and numerous archaeological cultures are labelled and defined by their burial customs, such as the Urnfield culture of the European Bronze Age.

doi:10.1086/590941. PMID 18665816. Wikidata Q45138244. Rajan P Adhikari; Cook, Gregory Murray; Lamont, Iain; Selwyn Lang; Heffernan, Helen Mary; John M B Smith (2002). "Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern methicillin-resistant Staphylococcus aureus". Journal of Antimicrobial Chemotherapy. 50 (6): 825–831. doi:10.1093/jac/dkf242. PMID 12461000. Wikidata Q40686052.

Sources: en.wikipedia.org

Reference notes

For Public Service. Virginia Dorothy Pitchers. For services to the community in Upton with Fishley, Norfolk. Lesley Porter. Principal's Personal Assistant, Oakgrove Integrated College, Derry-Londonderry. For services to Reconciliation in Northern Ireland. Elizabeth Shirley Powell. For services to the community in Brooke, Norfolk (to be dated 28th November 2023). Joan Prescott. For services to Young People and to the community in Melling, Merseyside. Derek Mark Preston. For services to the Northern Ireland Prison Service and to Charity in Northern Ireland. Kathleen Mary Prideaux. For services to the community in Allerford, Somerset. Herbert Proctor. For services to the community in Audley, Staffordshire. Margaret Douglas Rae. Lately President, Renfrewshire Girlguiding. For services to Girlguiding in Scotland. Mahbubur Rahman. For services to Charity and to the community in Oldham, Greater Manchester. Rehana Khanam Rahman. For services to the Bangladeshi Community. Helen Bridget Margaret Rayfield. Chair, Haringey Rhinos Rugby Football Club. For services to Rugby Union Football and to the community in the London Borough of Haringey. Alexander Ritchie. Trustee, New Deer Community Association and Founder Member, Buchan Heritage Society. For voluntary services to Cultural Heritage and to the community in North East Scotland. Patricia Christine Roberts. Lately Assistant District Commissioner, North Kent Cubs. For services to Young People in Kent. Jean Elna Roberts-Jones. For services to the community in Eastleigh and Fareham, Hampshire during Covid-19. Paul Rushworth.

== Optical excitation and ionization schemes == Optical ionization schemes are developed to produce element-selective ion source for various elements. Most of the elements of the periodic table have been resonantly ionized by using one of five major optical routes based on the principle of RIMS. The routes were formed by the absorption of two or three photons to achieve excitation and ionization and are provided on the basis of optically possible transitions between atomic levels in a process called the bound-bound transition. For an atom of the element to be promoted to a bound-continuum, the energies emitted from the photons must be within the energy range of the selected tunable lasers. Also, the ionization energy of the last emitted photon must exceed that of the atom. The optical ionization schemes are denoted by the amount of photons necessary to make the ion pair. For the first two Schemes 1 and 2, two photons (and processes) are involved. One photon excites the atom from the ground state to an intermediate state while the second photon ionizes the atom. In Schemes 3 and 4, three photons (and processes) are involved. The first two distinct photons create consecutive bound-bound transitions within the selected atom while the third photon is absorbed for ionization. Scheme 5 is a three-photon two-intermediate-level photoionization process. After the first two photons have been absorbed by the optical energy, the third photon achieves ionization. The RIS process can be used to ionize all elements on the periodic table, except helium and neon, using available lasers.

Another study of the PfSPZ vaccine was published in December 2022, reporting vaccine efficacy at up to 48% at 6 months follow up, and up to 46% efficacy at 18 months. Recent field studies have evaluated PfSPZ Vaccine in malaria-experienced African adults. A randomized, double-blind, placebo-controlled trial in Burkina Faso tested a three-dose intravenous regimen and reported vaccine efficacy of up to 48% at 6 months and 46% at 18 months against naturally acquired Plasmodium falciparum infection. The vaccine was well tolerated and immunogenic in this population. Additional studies in Equatorial Guinea examined multi-dose priming regimens of PfSPZ Vaccine followed by controlled human malaria infection (CHMI). Several schedules were found to be safe and capable of inducing significant protection against homologous challenge. By 2022 more than twenty clinical trials of PfSPZ-based products had been completed or were ongoing across Africa, Europe and the United States. PfSPZ Vaccine has also been evaluated in women of childbearing age and in participants who later became pregnant. Two randomized, double-blind, placebo-controlled trials in Mali investigated vaccination following presumptive antimalarial treatment. Across two transmission seasons, vaccine efficacy against Plasmodium falciparum parasitaemia in women of childbearing age ranged from 41% to 61%, depending on dose and year of follow-up. Among participants who conceived after vaccination, the vaccine was safe for mothers and infants and reduced the incidence of malaria parasitaemia during pregnancy.

== Long Range Patrol – Improved == While the MRE was lighter than the canned MCI and had more dietary energy than the LRP ration, it had certain problems. US Special Operations forces found it too bulky, and troops on maneuvers found some menu items were unsuited for easy digestion in cold-weather, high-altitude, high-temperature, or humid environments. While unofficial practice was to strip out items deemed "unnecessary", this also reduced the ration's dietary energy content. Faced with these problems, this forced the adoption of a specialized ration for light troops or commando units on extended field operations. In 1994, a new version of the LRP called the Food Packet, Long-Range Patrol – Improved (LRP-I) was created. It was an 11-ounce (310 g) ration that came in a brown plastic retort pouch that allowed the user to reconstitute and cook the ration directly in the pouch. This was an improvement over the earlier LRP packet, which had to be boiled or soaked in a canteen cup or other cookware.

Sources: en.wikipedia.org

Frequently asked questions